Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

β-catenin-independent regulation of Wnt target genes by RoR2 and ATF2/ATF4 in colon cancer cells.

Voloshanenko O, Schwartz U, Kranz D, Rauscher B, Linnebacher M, Augustin I, Boutros M.

Sci Rep. 2018 Feb 16;8(1):3178. doi: 10.1038/s41598-018-20641-5.

2.

Cellular vaccination of MLH1-/- mice - an immunotherapeutic proof of concept study.

Maletzki C, Gladbach YS, Hamed M, Fuellen G, Semmler ML, Stenzel J, Linnebacher M.

Oncoimmunology. 2017 Dec 14;7(3):e1408748. doi: 10.1080/2162402X.2017.1408748. eCollection 2018.

PMID:
29399413
3.

Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.

William D, Walther M, Schneider B, Linnebacher M, Classen CF.

PLoS One. 2018 Jan 19;13(1):e0191511. doi: 10.1371/journal.pone.0191511. eCollection 2018.

4.

Application of in vivo imaging techniques to monitor therapeutic efficiency of PLX4720 in an experimental model of microsatellite instable colorectal cancer.

Rohde S, Lindner T, Polei S, Stenzel J, Borufka L, Achilles S, Hartmann E, Lange F, Maletzki C, Linnebacher M, Glass Ä, Schwarzenböck SM, Kurth J, Hohn A, Vollmar B, Krause BJ, Jaster R.

Oncotarget. 2017 Jul 15;8(41):69756-69767. doi: 10.18632/oncotarget.19263. eCollection 2017 Sep 19.

5.

Colorectal carcinoma tumour budding and podia formation in the xenograft microenvironment.

Prall F, Maletzki C, Hühns M, Krohn M, Linnebacher M.

PLoS One. 2017 Oct 17;12(10):e0186271. doi: 10.1371/journal.pone.0186271. eCollection 2017.

6.

Deciphering molecular mechanisms of arginine deiminase-based therapy - Comparative response analysis in paired human primary and recurrent glioblastomas.

Maletzki C, Rosche Y, Riess C, Scholz A, William D, Classen CF, Kreikemeyer B, Linnebacher M, Fiedler T.

Chem Biol Interact. 2017 Dec 25;278:179-188. doi: 10.1016/j.cbi.2017.10.007. Epub 2017 Oct 5.

PMID:
28989041
7.

Amplification of the EGFR gene can be maintained and modulated by variation of EGF concentrations in in vitro models of glioblastoma multiforme.

William D, Mokri P, Lamp N, Linnebacher M, Classen CF, Erbersdobler A, Schneider B.

PLoS One. 2017 Sep 21;12(9):e0185208. doi: 10.1371/journal.pone.0185208. eCollection 2017.

8.

Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.

Wiegering A, Matthes N, Mühling B, Koospal M, Quenzer A, Peter S, Germer CT, Linnebacher M, Otto C.

Neoplasia. 2017 Apr;19(4):301-309. doi: 10.1016/j.neo.2017.01.007. Epub 2017 Mar 9.

9.

Frameshift mutational target gene analysis identifies similarities and differences in constitutional mismatch repair-deficiency and Lynch syndrome.

Maletzki C, Huehns M, Bauer I, Ripperger T, Mork MM, Vilar E, Klöcking S, Zettl H, Prall F, Linnebacher M.

Mol Carcinog. 2017 Jul;56(7):1753-1764. doi: 10.1002/mc.22632. Epub 2017 Mar 30.

PMID:
28218421
10.

Optimized creation of glioblastoma patient derived xenografts for use in preclinical studies.

William D, Mullins CS, Schneider B, Orthmann A, Lamp N, Krohn M, Hoffmann A, Classen CF, Linnebacher M.

J Transl Med. 2017 Feb 9;15(1):27. doi: 10.1186/s12967-017-1128-5.

11.

Tumor Take Rate Optimization for Colorectal Carcinoma Patient-Derived Xenograft Models.

Gock M, Kühn F, Mullins CS, Krohn M, Prall F, Klar E, Linnebacher M.

Biomed Res Int. 2016;2016:1715053. doi: 10.1155/2016/1715053. Epub 2016 Nov 23.

12.

Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells.

Schäfer C, Göder A, Beyer M, Kiweler N, Mahendrarajah N, Rauch A, Nikolova T, Stojanovic N, Wieczorek M, Reich TR, Tomicic MT, Linnebacher M, Sonnemann J, Dietrich S, Sellmer A, Mahboobi S, Heinzel T, Schneider G, Krämer OH.

Cell Signal. 2017 Jan;29:218-225. doi: 10.1016/j.cellsig.2016.11.002. Epub 2016 Nov 9.

PMID:
27838375
13.

Generation of Xenotransplants from Human Cancer Biopsies to Assess Anti-cancer Activities of HDACi.

Mullins CS, Bock S, Krohn M, Linnebacher M.

Methods Mol Biol. 2017;1510:217-229.

PMID:
27761824
14.

The mutational profile and infiltration pattern of murine MLH1-/- tumors: concurrences, disparities and cell line establishment for functional analysis.

Maletzki C, Beyrich F, Hühns M, Klar E, Linnebacher M.

Oncotarget. 2016 Aug 16;7(33):53583-53598. doi: 10.18632/oncotarget.10677.

15.

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.

Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, Cancelliere C, Linnebacher M, Corti G, Truini M, Siravegna G, Grasselli J, Gallicchio M, Bernards R, Schellens JH, Tabernero J, Engelman JA, Sartore-Bianchi A, Bardelli A, Siena S, Corcoran RB, Di Nicolantonio F.

Cancer Res. 2016 Aug 1;76(15):4504-15. doi: 10.1158/0008-5472.CAN-16-0396. Epub 2016 Jun 16.

16.

Generation, Characterization and Application of Antibodies Directed against HERV-H Gag Protein in Colorectal Samples.

Mullins CS, Hühns M, Krohn M, Peters S, Cheynet V, Oriol G, Guillotte M, Ducrot S, Mallet F, Linnebacher M.

PLoS One. 2016 Apr 27;11(4):e0153349. doi: 10.1371/journal.pone.0153349. eCollection 2016.

17.

After Intestinal Transplantation Kidney Function Is Impaired by Downregulation of Epithelial Ion Transporters in the Ileum.

Reiner J, Hsieh CJ, Straarup C, Bodammer P, Schäffler H, Graepler F, Stüker D, Kratt T, Linnebacher M, Nadalin S, Witte M, Königsrainer A, Lamprecht G.

Transplant Proc. 2016 Mar;48(2):499-506. doi: 10.1016/j.transproceed.2015.12.068.

PMID:
27109987
18.

Establishment and characterization of HROC69 - a Crohn´s related colonic carcinoma cell line and its matched patient-derived xenograft.

Kuehn F, Mullins CS, Krohn M, Harnack C, Ramer R, Krämer OH, Klar E, Huehns M, Linnebacher M.

Sci Rep. 2016 Apr 18;6:24671. doi: 10.1038/srep24671.

19.

Functional Characterization and Drug Response of Freshly Established Patient-Derived Tumor Models with CpG Island Methylator Phenotype.

Maletzki C, Huehns M, Knapp P, Waukosin N, Klar E, Prall F, Linnebacher M.

PLoS One. 2015 Nov 30;10(11):e0143194. doi: 10.1371/journal.pone.0143194. eCollection 2015.

20.

Expression of young HERV-H loci in the course of colorectal carcinoma and correlation with molecular subtypes.

Pérot P, Mullins CS, Naville M, Bressan C, Hühns M, Gock M, Kühn F, Volff JN, Trillet-Lenoir V, Linnebacher M, Mallet F.

Oncotarget. 2015 Nov 24;6(37):40095-111. doi: 10.18632/oncotarget.5539.

21.

Celecoxib increases lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1.

Schellhorn M, Haustein M, Frank M, Linnebacher M, Hinz B.

Oncotarget. 2015 Nov 17;6(36):39342-56. doi: 10.18632/oncotarget.5745.

22.

Optimizing the process of nucleofection for professional antigen presenting cells.

Mullins CS, Wegner T, Klar E, Classen CF, Linnebacher M.

BMC Res Notes. 2015 Sep 24;8:472. doi: 10.1186/s13104-015-1446-8.

23.

Stage-specific frequency and prognostic significance of aneuploidy in patients with sporadic colorectal cancer--a meta-analysis and current overview.

Laubert T, Freitag-Wolf S, Linnebacher M, König A, Vollmar B, Habermann JK; North German Tumorbank of Colorectal Cancer (ColoNet) consortium.

Int J Colorectal Dis. 2015 Aug;30(8):1015-28. doi: 10.1007/s00384-015-2259-x. Epub 2015 Jun 9. Review.

PMID:
26054386
24.

Assessing quality and functionality of DNA isolated from FFPE tissues through external quality assessment in tissue banks.

Ahmad-Nejad P, Duda A, Sucker A, Werner M, Bronsert P, Stickeler E, Reifenberger G, Malzkorn B, Oberländer M, Habermann JK, Bruch HP, Linnebacher M, Schadendorf D, Neumaier M.

Clin Chem Lab Med. 2015 Nov;53(12):1927-34. doi: 10.1515/cclm-2014-1202.

PMID:
26053008
25.

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.

Medico E, Russo M, Picco G, Cancelliere C, Valtorta E, Corti G, Buscarino M, Isella C, Lamba S, Martinoglio B, Veronese S, Siena S, Sartore-Bianchi A, Beccuti M, Mottolese M, Linnebacher M, Cordero F, Di Nicolantonio F, Bardelli A.

Nat Commun. 2015 Apr 30;6:7002. doi: 10.1038/ncomms8002.

26.

Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.

Fiedler T, Strauss M, Hering S, Redanz U, William D, Rosche Y, Classen CF, Kreikemeyer B, Linnebacher M, Maletzki C.

Cancer Biol Ther. 2015;16(7):1047-55. doi: 10.1080/15384047.2015.1026478. Epub 2015 Mar 16.

27.

MicroRNA-mRNA interactions in colorectal cancer and their role in tumor progression.

Amirkhah R, Schmitz U, Linnebacher M, Wolkenhauer O, Farazmand A.

Genes Chromosomes Cancer. 2015 Mar;54(3):129-41. doi: 10.1002/gcc.22231. Review.

PMID:
25620079
28.

Reactivity against microsatellite instability-induced frameshift mutations in patients with inflammatory bowel disease.

Kuehn F, Klar E, Bliemeister A, Linnebacher M.

World J Gastroenterol. 2015 Jan 7;21(1):221-8. doi: 10.3748/wjg.v21.i1.221.

29.

Establishment and characterization of cell lines from chromosomal instable colorectal cancer.

Maletzki C, Gock M, Randow M, Klar E, Huehns M, Prall F, Linnebacher M.

World J Gastroenterol. 2015 Jan 7;21(1):164-76. doi: 10.3748/wjg.v21.i1.164.

30.

E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts.

Wiegering A, Korb D, Thalheimer A, Kämmerer U, Allmanritter J, Matthes N, Linnebacher M, Schlegel N, Klein I, Ergün S, Germer CT, Otto C.

Neoplasia. 2014 Nov 20;16(11):972-81. doi: 10.1016/j.neo.2014.09.008. eCollection 2014 Nov.

31.

Biological and molecular effects of small molecule kinase inhibitors on low-passage human colorectal cancer cell lines.

Lange F, Franz B, Maletzki C, Linnebacher M, Hühns M, Jaster R.

Biomed Res Int. 2014;2014:568693. doi: 10.1155/2014/568693. Epub 2014 Sep 17.

32.

Accounting for randomness in measurement and sampling in studying cancer cell population dynamics.

Ghavami S, Wolkenhauer O, Lahouti F, Ullah M, Linnebacher M.

IET Syst Biol. 2014 Oct;8(5):230-41. doi: 10.1049/iet-syb.2013.0031.

PMID:
25257023
33.

Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1.

Haustein M, Ramer R, Linnebacher M, Manda K, Hinz B.

Biochem Pharmacol. 2014 Nov 15;92(2):312-25. doi: 10.1016/j.bcp.2014.07.014. Epub 2014 Jul 25.

PMID:
25069049
34.

The impact of pyrvinium pamoate on colon cancer cell viability.

Wiegering A, Uthe FW, Hüttenrauch M, Mühling B, Linnebacher M, Krummenast F, Germer CT, Thalheimer A, Otto C.

Int J Colorectal Dis. 2014 Oct;29(10):1189-98. doi: 10.1007/s00384-014-1975-y. Epub 2014 Jul 26.

PMID:
25060218
35.

Host defense peptides for treatment of colorectal carcinoma - a comparative in vitro and in vivo analysis.

Maletzki C, Klier U, Marinkovic S, Klar E, Andrä J, Linnebacher M.

Oncotarget. 2014 Jun 30;5(12):4467-79.

36.

PTEN mutation, loss of heterozygosity, promoter methylation and expression in colorectal carcinoma: two hits on the gene?

Hühns M, Salem T, Schneider B, Krohn M, Linnebacher M, Prall F.

Oncol Rep. 2014 May;31(5):2236-44. doi: 10.3892/or.2014.3097. Epub 2014 Mar 19.

PMID:
24647592
37.

Combinations of TLR ligands: a promising approach in cancer immunotherapy.

Stier S, Maletzki C, Klier U, Linnebacher M.

Clin Dev Immunol. 2013;2013:271246. doi: 10.1155/2013/271246. Epub 2013 Nov 25.

38.

Microsatellite instability in hematological malignancies: Hypermutation vs. immune control-who is challenging who?

Maletzki C, Stier S, Linnebacher M.

Oncoimmunology. 2013 Aug 1;2(8):e25419. Epub 2013 Jul 1.

39.

Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison.

Mullins CS, Schneider B, Stockhammer F, Krohn M, Classen CF, Linnebacher M.

PLoS One. 2013 Aug 7;8(8):e71070. doi: 10.1371/journal.pone.0071070. eCollection 2013.

40.

Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib.

Ramer R, Walther U, Borchert P, Laufer S, Linnebacher M, Hinz B.

J Lipid Res. 2013 Nov;54(11):3116-29. doi: 10.1194/jlr.M042283. Epub 2013 Aug 12.

41.

Mistletoe lectin has a shiga toxin-like structure and should be combined with other Toll-like receptor ligands in cancer therapy.

Maletzki C, Linnebacher M, Savai R, Hobohm U.

Cancer Immunol Immunother. 2013 Aug;62(8):1283-92. doi: 10.1007/s00262-013-1455-1. Epub 2013 Jul 6.

PMID:
23832140
42.

Cilengitide response in ultra-low passage glioblastoma cell lines: relation to molecular markers.

Mullins CS, Schubert J, Schneider B, Linnebacher M, Classen CF.

J Cancer Res Clin Oncol. 2013 Aug;139(8):1425-31. doi: 10.1007/s00432-013-1457-6. Epub 2013 Jun 8.

PMID:
23749036
43.

Frameshift-derived neoantigens constitute immunotherapeutic targets for patients with microsatellite-instable haematological malignancies: frameshift peptides for treating MSI+ blood cancers.

Maletzki C, Schmidt F, Dirks WG, Schmitt M, Linnebacher M.

Eur J Cancer. 2013 Jul;49(11):2587-95. doi: 10.1016/j.ejca.2013.02.035. Epub 2013 Apr 2.

PMID:
23561850
44.

Tumor-infiltrating B cells come into vogue.

Linnebacher M.

World J Gastroenterol. 2013 Jan 7;19(1):8-11. doi: 10.3748/wjg.v19.i1.8.

45.

Establishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas.

Maletzki C, Stier S, Gruenert U, Gock M, Ostwald C, Prall F, Linnebacher M.

PLoS One. 2012;7(12):e52485. doi: 10.1371/journal.pone.0052485. Epub 2012 Dec 31.

46.

The "North German Tumor Bank of Colorectal Cancer": status report after the first 2 years of support by the German Cancer Aid Foundation.

Oberländer M, Linnebacher M, König A, Bogoevska V, Brodersen C, Kaatz R, Krohn M, Hackmann M, Ingenerf J, Christoph J, Mate S, Prokosch HU, Yekebas EF, Thorns C, Büning J, Prall F, Uhlig R, Roblick UJ, Izbicki JR, Klar E, Bruch HP, Vollmar B, Habermann JK; ColoNet consortium.

Langenbecks Arch Surg. 2013 Feb;398(2):251-8. doi: 10.1007/s00423-012-1043-4. Epub 2013 Jan 8.

PMID:
23292500
47.

Single nucleotide polymorphism array analysis of microsatellite-stable, diploid/near-diploid colorectal carcinomas without the CpG island methylator phenotype.

Linnebacher M, Ostwald C, Koczan D, Salem T, Schneider B, Krohn M, Ernst M, Prall F.

Oncol Lett. 2013 Jan;5(1):173-178. Epub 2012 Oct 30.

48.

COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells.

Ramer R, Heinemann K, Merkord J, Rohde H, Salamon A, Linnebacher M, Hinz B.

Mol Cancer Ther. 2013 Jan;12(1):69-82. doi: 10.1158/1535-7163.MCT-12-0335. Epub 2012 Dec 7.

49.

Reevaluating the concept of treating experimental tumors with a mixed bacterial vaccine: Coley's Toxin.

Maletzki C, Klier U, Obst W, Kreikemeyer B, Linnebacher M.

Clin Dev Immunol. 2012;2012:230625. doi: 10.1155/2012/230625. Epub 2012 Nov 11.

50.

Tumor-infiltrating B cells: The ignored players in tumor immunology.

Linnebacher M, Maletzki C.

Oncoimmunology. 2012 Oct 1;1(7):1186-1188.

Supplemental Content

Loading ...
Support Center